Egfr
A topic on our watch list — we track its coverage across 6 domains, including Pubmed Targeted, Gi Journal and Industry News.
Coverage of Egfr is holding steady : 4 signals on the latest tracked day, level with its three-week baseline of 4, across 3 domains. That makes it the #169 most-covered of the 349 concerns we track.
What’s changed
- EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study. · Clin Cancer Res · 2026-08-24
- RAF/MEK Clamp Inhibition with Avutometinib and Cetuximab in RAF1 S257L-Mutated, Anti-EGFR-Refractory Metastatic Colorectal Cancer in Gaucher's disease. · Oncologist · 2026-08-19
- High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring · European Journal of Cancer · 2026-08-16
- Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival” · Journal of Clinical Oncology · 2026-08-13
- Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study · Journal of Clinical Oncology · 2026-08-12
- Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy. · Cell Death Differ · 2026-08-11
What the reporting says
It shows up alongside Colorectal Cancer (43), Braf (20 — acquisition ×2), KRAS (17 — acquisition ×2), Lung Cancer (15 — acquisition ×2), Immunotherapy (9), Mapk (8), FDA (8).
Two steps out: AI (through Colorectal Cancer, 43 shared stories on the weaker link); Chen (through Colorectal Cancer, 43 shared stories on the weaker link); ctDNA (through Colorectal Cancer, 43 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 43 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 57 separate days — concentrated in Oncology and Pubmed Targeted.